Oral GLP-1 Drug Orforglipron Shows Promising Weight Loss and Safety in First Human Trial

What the researchers found

In Part A (single dose, n=32), orforglipron showed dose-proportional pharmacokinetics with a half-life of 24.6–35.3 hours across doses of 0.3–6 mg. In Part B (multiple dose, n=60), 4 weeks of daily dosing with escalation to final target doses of 2–24 mg resulted in extended half-lives of 48.1–67.5 hours.

Participants receiving orforglipron lost up to 5.4 kg of body weight after 4 weeks compared to 2.4 kg with placebo (P < 0.05). Fasting glucose levels decreased across the treatment period, and gastric emptying was delayed on Day 28 — all consistent with GLP-1 receptor activation. The most common adverse events were gastrointestinal, similar to injectable GLP-1 receptor agonists.

Why it matters

Current GLP-1 receptor agonists for weight loss and diabetes require injection, which limits adoption. An oral non-peptide alternative that works similarly could dramatically expand access to these treatments. Orforglipron's once-daily dosing without food or water restrictions also improves on existing oral GLP-1 options like oral semaglutide, which requires fasting.

How the study worked

This was a Phase 1, double-blind, placebo-controlled, randomized study in healthy adults aged 18–65 with BMI 20–40 kg/m² and HbA1c below 6.5%. Part A tested single escalating doses (0.3–6 mg) in four cohorts. Part B tested 4 weeks of daily dosing with weekly dose escalation to four final target doses (2–24 mg). Safety, pharmacokinetics, body weight, fasting glucose, and gastric emptying were assessed.

What this study cannot tell us

This was a Phase 1 study in healthy participants, not patients with diabetes or obesity. The treatment period was only 4 weeks, too short to assess long-term efficacy or safety. The sample size was small (92 total, split across multiple dose groups). Efficacy endpoints were exploratory, and larger Phase 2/3 trials in target patient populations are needed.

How to read the evidence

This is a Phase 1 clinical trial focused on safety and pharmacokinetics in healthy volunteers. While well-designed (randomized, double-blind, placebo-controlled), it was not powered for efficacy and used a short treatment duration in a non-target population.

When this study was published

Published in 2023, this Phase 1 data is part of the active clinical development program for orforglipron. Later-phase trials with efficacy data have since been reported.

The bigger picture

The development of oral non-peptide GLP-1 receptor agonists represents a potential paradigm shift in obesity and diabetes treatment. If orforglipron succeeds in later trials, it could make GLP-1-based therapy accessible to the millions of patients who are unwilling or unable to use injectable medications, while also simplifying treatment compared to oral semaglutide's strict dosing requirements.

Questions still open

• How does orforglipron's weight loss efficacy compare to injectable semaglutide or tirzepatide over longer treatment periods?
• Will orforglipron maintain its favorable safety profile in patients with type 2 diabetes or obesity with comorbidities?
• Could the non-peptide structure of orforglipron offer advantages in terms of immunogenicity or long-term tolerability?

Common questions

Read the original research

Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.

Diabetes, obesity & metabolism, 25(9), 2634-2641

Citation

Pratt, Edward; Ma, Xiaosu; Liu, Rong; Robins, Deborah; Haupt, Axel; Coskun, Tamer; Sloop, Kyle W; Benson, Charles. (2023). Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.. Diabetes, obesity & metabolism, 25(9), 2634-2641. https://doi.org/10.1111/dom.15184